|
Aug 30
|
Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131
|
|
Aug 26
|
Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia
|
|
Aug 23
|
Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq
|
|
Jul 23
|
Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months
|
|
May 15
|
Q1 2024 Cellectar Biosciences Inc Earnings Call
|
|
May 15
|
Cellectar Biosciences Inc (CLRB) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
|
May 14
|
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
|
|
May 8
|
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
|
|
May 7
|
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
|
|
Mar 29
|
Cellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven?
|
|
Mar 28
|
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript
|
|
Mar 28
|
Q4 2023 Cellectar Biosciences Inc Earnings Call
|
|
Mar 27
|
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
|
|
Mar 20
|
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
|
|
Mar 14
|
Cellectar Biosciences to Present at the 36th Annual Roth Conference
|
|
Mar 4
|
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
|
|
Jan 25
|
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
|
|
Jan 22
|
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
|
|
Jan 16
|
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
|
|
Jan 12
|
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
|